Yes it’s a pretty detailed outline of what goes into implementing such a device into the current ‘standard of care’ for these US organisations and improving that standard of care.
There is obviously lots more to this process than the average watcher/shareholder might think. I don’t think these healthcare institutions would go to the trouble below if it was a niche problem or the wheezo had marginal utility- it’s a great vindication for wheezo:
“ Onboarding of Patients:
Following execution of the contracted engagement with a medical institution/healthcare organisation by Respiri’s RPM partner, contract patient generation (“on-boarding of patients” may take 6 months to commence given the due diligence and authorisation processes that each medical institution/healthcare organisation is required to undertake prior to rolling out the wheezo® RPM program. This includes securing approval from the medical advisory board and ethics committee to ensure that the wheezo® device fits within the standards of care used by the medical institution/healthcare organisation for its patients in the management of respiratory disease.
Prior to onboarding patients, Access Telehealth contracts with each medical institution/healthcare organisation to complete a number of critical milestone steps before a program is able to go ‘live’ prior to onboarding of patients. These include:
• patient eligibility and protocol finalisation,
• patient management and alert plan development,
• product training for physicians and medical staff,
• technical integration (billing and reporting alignment) into existing medical institution systems,
• claims review to confirm the wheezo® RPM program qualifies for RPM Current Procedural Terminology (CPT) reimbursement through Centers for Medicare and Medicaid Services (CMS) and private insurers,
• Financial system integration to ensure payment,
.
Legal, privacy and data security assessment
, • device logistics, and
marketing”
Reimbursement of wheezo® RPM program is the next massive step - watch who starts paying attention when this is confirmed imho. When the system starts paying (in the US that’s the various health insurers) then this is a game changer for RSH.
RSH Price at posting:
5.2¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
may take 6 months to commence given the due diligence and authorisation processes that each medical institution/healthcare organisation is required to undertake prior to rolling out the wheezo® RPM program. This includes securing approval from the medical advisory board and ethics committee to ensure that the wheezo® device fits within the standards of care used by the medical institution/healthcare organisation for its patients in the management of respiratory disease.
(20min delay)